PT - JOURNAL ARTICLE AU - , AU - Hall, Matthew AU - Pritchard, Mark AU - Dankwa, Emmanuelle A. AU - Baillie, J. Kenneth AU - Carson, Gail AU - Docherty, Annemarie AU - Donnelly, Christl A. AU - Dunning, Jake AU - Fraser, Christophe AU - Hardwick, Hayley AU - Harrison, Ewen M. AU - Holden, Karl A. AU - Kennon, Kalynn AU - Lee, James AU - Openshaw, Peter J.M. AU - Plotkin, Daniel AU - Rojek, Amanda AU - Russell, Clark D. AU - Semple, Malcolm G. AU - Sigfrid, Louise AU - Horby, Peter AU - Olliaro, Piero AU - Merson, Laura AU - , TI - ISARIC Clinical Data Report 8 June 2020 AID - 10.1101/2020.07.17.20155218 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.17.20155218 4099 - http://medrxiv.org/content/early/2020/07/25/2020.07.17.20155218.short 4100 - http://medrxiv.org/content/early/2020/07/25/2020.07.17.20155218.full AB - ISARIC (International Severe Acute Respiratory and emerging Infections Consortium) partnerships and outbreak preparedness initiatives enabled the rapid launch of standardised clinical data collection on COVID-19 in Jan 2020. Extensive global uptake of this resource has resulted in a large, standardised collection of comprehensive clinical data from hundreds of sites across dozens of countries. Data are analysed regularly and reported publicly to inform patient care and public health response. This report is a part of a series and includes the results of data analysis on 8 June 2020.We thank all of the data contributors for their ongoing support.As of 8JUN20, data have been entered for 67,130 patients from 488 sites across 37 countries. For this report, we show data for 42,656 patients with confirmed disease who were enrolled >14 days prior.This update includes about 2,400 new cases from France, and we thank these collaborators for this significant addition to the dataset.Some highlights from this report The median time from onset of symptoms to hospital admission is 5 days, but a proportion of patients take longer to get to the hospital (average 14.6 days, standard deviation 8.1).COVID-19 patients tend to require prolonged hospitalisation; of the 88% with a known outcome the median length of admission to death or discharge is 8 days and the mean 11.5. 17% of patients were admitted to ICU/HDU, about 40% of these on the very day of hospital admission.Antibiotics were given to 83% of patients, antivirals to 9%, steroids to 15%, which becomes 93%, 50% and 27%, respectively for those admitted to ICU/HDU. Attention has been called on overuse of antibiotics and need to adhere to antibiotic stewardship principles.67% of patients received some degree of oxygen supplementation: of these 23.4% received NIV and 15% IMV. This relatively high proportion of oxygen use will have implications for oxygen surge planning in healthcare facilities. Some centres may need to plan to boost capacity to deliver oxygen therapy if this is not readily available. WHO provides operational advice on surge strategy here https://apps.who.int/iris/bitstream/handle/10665/331746/WHO-2019-nCoV-Oxygen_sources-2020.1-eng.pdfISARIC (International Severe Acute Respiratory and Emerging Infections Consortium)A global federation of clinical research networks, providing a proficient, coordinated, and agile research response to outbreak-prone infectious diseasesCOVID-19 Report: 08 June 2020Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://isaric.net/ccp/ https://isaric4c.net/ Funding StatementThis work is supported by grants fincluding: the National Institute for Health Research (NIHR; award CO-CIN-01), the Medical Research Council (MRC; grant MC_PC_19059), the NIHR Health Protection Research Unit in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England (PHE), in collaboration with Liverpool School of Tropical Medicine and the University of Oxford (NIHR award 200907), Wellcome Trust and Department for International Development (DID; 215091/Z/18/Z), and the Bill and Melinda Gates Foundation (OPP1209135), and Liverpool Experimental Cancer Medicine Centre for providing infrastructure support for this research (grant reference C18616/A25153). Contents of the publication are those of the authors and not necessarily reflect those of the funders. Additional funding support can be viewed at https://isaric.tghn.org/covid-19-data-management-hosting-contributors/.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee approval was given by the WHO Ethics Review Committee (RPC571 and RPC572, 25 April 2013). Institutional approval was additionally obtained by participating sites including the South Central - Oxford C Research Ethics Committee in England (Ref 13/SC/0149), the Scotland A Research Ethics Committee (Ref 20/SS/0028) for the UK, which represents the majority of the data. Other institutional and national approvals are in place as per local requirements.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe welcome applications for UK data through the ISARIC 4C Independent Data and Material Access Committee (https://isaric4c.net). Requests for access to non-UK data can be sent to covid19@iddo.org. https://isaric4c.net https://www.iddo.org/research-themes/covid-19